ATR and cancer: This burden can be exploited for cancer treatment by the use of genotoxic drugs that further increase RS and/or by inhibiting the ATR pathway (Lecona and Fernandez-Capetillo, 2018; Ubhi and Brown, 2019; Zhu et al., 2020).